Predictors of Functional and Anatomic Outcomes in Patients with Diabetic Macular Edema Treated with Ranibizumab

Ophthalmology

Volumn 122, Issue 7, 2015, Pages 1395-1401

  Sophie, Raafay ^a   Lu, Na ^b   Campochiaro, Peter A ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RANIBIZUMAB; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADULT; ARTICLE; BEST CORRECTED VISUAL ACUITY; CARDIOVASCULAR DISEASE; CENTRAL FOVEAL THICKNESS; CONTROLLED STUDY; DIABETIC MACULAR EDEMA; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; LASER COAGULATION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PIGMENT EPITHELIUM; POST HOC ANALYSIS; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VISUAL ACUITY; VISUAL SYSTEM PARAMETERS; AGED; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; DIABETIC RETINOPATHY; INTRAVITREAL DRUG ADMINISTRATION; MACULAR EDEMA; MIDDLE AGED; OPTICAL COHERENCE TOMOGRAPHY; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; RETINA FOVEA; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; DIABETIC RETINOPATHY; FEMALE; FOVEA CENTRALIS; HUMANS; INTRAVITREAL INJECTIONS; MACULAR EDEMA; MALE; MIDDLE AGED; TOMOGRAPHY, OPTICAL COHERENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; YOUNG ADULT;

EID: 84937724063     PISSN: 01616420     EISSN: 15494713     Source Type: Journal    
DOI: 10.1016/j.ophtha.2015.02.036     Document Type: Article

References (12)

1. J. Ding, and T.Y. Wong Current epidemiology of diabetic retinopathy and diabetic macular edema Curr Diab Rep 12 2012 346 354
2. Q.D. Nguyen, S. Tatlipinar, S.M. Shah, and et al. Vascular endothelial growth factor is a critical stimulus for diabetic macular edema Am J Ophthalmol 142 2006 961 969
3. Q.D. Nguyen, S.M. Shah, J.S. Heier, and et al. Primary end point (six months) results of the Ranibizumab for Edema of the mAcula in Diabetes (READ-2) Study Ophthalmology 116 2009 2175 2181
4. Q.D. Nguyen, D.M. Brown, D.M. Marcus, and et al. Ranibizumab for diabetic macular edema. Results from 2 phase III randomized trials: RISE and RIDE Ophthalmology 119 2012 789 801
5. Early Treatment Diabetic Retinopathy Study Group Early photocoagulation for diabetic retinopathy. ETDRS report no 9 Ophthalmology 98 suppl 1991 767 785
6. The Diabetic Retinopathy Clinical Research Network Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema Ophthalmology 117 2010 1064 1077
7. D.V. Do, Q.D. Nguyen, D. Boyer, and et al. One-year outcomes of the DA VINCI study of VEGF Trap-Eye in eyes with diabetic macular edema Ophthalmology 119 2012 1658 1665
8. R.B. Bhistikul, P.A. Campochiaro, H. Shapiro, and R. Rubio Predictive value in retinal vein occlusions of early versus late or incomplete ranibizumab response defined by optical coherence tomography Ophthalmology 120 2013 1057 1063
9. R. Channa, R. Sophie, A.A. Khwaja, and et al. Factors affecting visual outcomes in patients with diabetic macular edema treated with ranibizumab Eye (Lond) 28 2013 269 278
10. S.B. Bressler, H. Qin, R.W. Beck, and et al. Factors associated with changes in visual acuity and central subfield thickness at 1 year after treatment for diabetic macular edema with ranibizumab Arch Ophthalmol 130 2012 1153 1161
11. W.C. Knowler, P.H. Bennett, and E.J. Ballintine Increased incidence of retinopathy in diabetics with elevated blood pressure N Engl J Med 302 1980 645 650
12. R. Klein, and B.E. Klein Blood pressure control and diabetic retinopathy Br J Ophthalmol 86 2002 365 367